DIACC-1020

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameDIACC-1020

Drug Alias Nametrans CD4 immunotherapy (Diaccurate)DIACC-1020

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody

Mechanisms of ActionT-cell surface antigen CD4 agonists

TargetsT-cell surface antigen CD4

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryFrance

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesEvexta Bio SA

China Registration ClassN/A

Active CompaniesN/A

Inactive CompaniesEvexta Bio SA

Active IndicationsN/A

Inactive IndicationsSolid tumours

ATC CodeN/A